- Sacco brings significant rare disease
commercial leadership experience including product launch and
global commercial strategy
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage
biopharmaceutical company focused on the treatment of serious
diseases in which protein growth factors play a fundamental role,
today announced the appointment of Tracey M. Sacco as Chief
Commercial Officer. Ms. Sacco brings extensive biopharmaceutical
industry experience, including product launch and global commercial
strategy. At Scholar Rock, she will build and lead all commercial
functions, including sales, marketing, market access, and
commercial operations. Her first priority will be preparing the
company for the potential commercial launch of apitegromab, the
company’s Phase 3 investigational candidate for spinal muscular
atrophy (SMA).
“Our ongoing Phase 3 SAPPHIRE trial is our top priority, and we
are committed to the patients who we believe may benefit from
apitegromab. To this end, we are thrilled to welcome Tracey to
Scholar Rock’s executive team and leverage her depth of commercial
experience as the company’s Chief Commercial Officer,” said Dr. Jay
Backstrom, M.D., M.P.H., President & Chief Executive Officer of
Scholar Rock. “Tracey is an exceptional leader with a proven track
record of building commercial organizations and launching new
products in the rare disease area. She brings capabilities and deep
expertise that will complement our current activities and help us
maximize the significant opportunity before us.”
“Scholar Rock has developed a differentiated and a validated
scientific approach to addressing devastating illnesses and has the
potential to bring truly practice-changing medicines to patients.
I’m thrilled to be joining the Scholar Rock team at a time with so
much positive momentum and look forward to contributing to the
success of the apitegromab program by preparing for the company’s
first commercial launch,” said Ms. Sacco.
Ms. Sacco joins Scholar Rock with nearly two decades in the
biopharmaceutical industry. Much of her career has focused on rare
disease, where she has worked on programs from early-stage
development through launch. Most recently, Ms. Sacco worked at The
Nemetz Group, where she served as a strategic partner to
biopharmaceutical companies on commercialization and corporate
strategy. Previously, she held positions of increasing
responsibility at Acceleron Pharma, most recently serving as Senior
Vice President, Global Strategic Marketing. She was a key architect
of the U.S. launch of REBLOZYL® for myelodysplastic syndromes and
beta-thalassemia. Prior to Acceleron, Ms. Sacco held roles in
commercial strategy and business development at Sanofi (formerly
Genzyme), Oscient Pharmaceuticals, and Pfizer.
Ms. Sacco holds an M.B.A. from NYU Stern School of Business and
a B.A. in Economics and Sociology from Boston College. She is a
member of the Life Science Cares Board of Advisors.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer, and
fibrosis. Scholar Rock’s approach to targeting the molecular
mechanisms of growth factor activation enabled it to develop a
proprietary platform for the discovery and development of
monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our
investors and the public using our company website
www.scholarrock.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on Twitter and
LinkedIn. The information that we post on our website or on Twitter
or LinkedIn could be deemed to be material information. As a
result, we encourage investors, the media and others interested to
review the information that we post there on a regular basis. The
contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding Scholar
Rock’s future expectations, plans and prospects, including without
limitation, Scholar Rock’s expectations regarding its growth,
strategy, progress and timing of its clinical trials for
apitegromab, SRK-181, and other product candidates and indication
selection and development timing, the ability of any individual to
affect the performance of the company, the ability of any product
candidate to perform in humans in a manner consistent with earlier
nonclinical, preclinical or clinical trial data, and the potential
of its product candidates and proprietary platform. The use of
words such as “may,” “might,” “could,” “will,” “should,” “expect,”
“plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,”
“future,” “potential,” or “continue,” and other similar expressions
are intended to identify such forward-looking statements. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
without limitation, that preclinical and clinical data, including
the results from the Phase 2 clinical trial of apitegromab, or Part
A of the Phase 1 clinical trial of SRK-181, are not predictive of,
may be inconsistent with, or more favorable than, data generated
from future clinical trials of the same product candidate,
including, without limitation, the Phase 3 clinical trial of
apitegromab in SMA or Part B of the Phase 1 clinical trial of
SRK-181, Scholar Rock’s ability to provide the financial support,
resources and expertise necessary to identify and develop product
candidates on the expected timeline, the data generated from
Scholar Rock’s nonclinical and preclinical studies and clinical
trials, information provided or decisions made by regulatory
authorities, competition from third parties that are developing
products for similar uses, Scholar Rock’s ability to obtain,
maintain and protect its intellectual property, Scholar Rock’s
dependence on third parties for development and manufacture of
product candidates including, without limitation, to supply any
clinical trials, Scholar Rock’s ability to manage expenses and to
obtain additional funding when needed to support its business
activities and establish and maintain strategic business alliances
and new business initiatives, and the impacts of public health
pandemics such as COVID-19 on business operations and expectations,
as well as those risks more fully discussed in the section entitled
"Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for
the quarter ended September 30, 2022, as well as discussions of
potential risks, uncertainties, and other important factors in
Scholar Rock’s subsequent filings with the Securities and Exchange
Commission. Any forward-looking statements represent Scholar Rock’s
views only as of today and should not be relied upon as
representing its views as of any subsequent date. All information
in this press release is as of the date of the release, and Scholar
Rock undertakes no duty to update this information unless required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230206005061/en/
Scholar Rock: Investors Rushmie Nofsinger Scholar
Rock rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Media Ariane Lovell Finn Partners
ariane.lovell@finnpartners.com media@scholarrock.com
917-565-2204
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024